Tags : PBO

Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv

Vartika Singh February 22, 2019

Shots: The P-III METEORIC-HF study involves assessing of omecamtiv mecarbil (25/50 mg, bid) vs PBO in 270 patients in the ratio (2:1) on exercise capacity as determined by cardiopulmonary exercise […]readmore

Tags : PBO

Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : PBO

Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company